Drug Search Results
More Filters [+]

CLR-457

Alternative Names: clr-457, clr457, clr 457
Latest Update: 2021-12-03
Latest Update Note: Clinical Trial Update

Product Description

CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor.

Mechanisms of Action: PI3K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CLR-457

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Oncology Solid Tumor Unspecified

Phase 1: Breast Cancer|Endometrial Cancer|Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JapicCTI-152791

P2

Terminated

Oncology Solid Tumor Unspecified

2017-09-01

CCLR457X2101

P1

Terminated

Endometrial Cancer|Lung Cancer|Breast Cancer

2015-11-12

42%

2014-000316-34

P2

Completed

Oncology Solid Tumor Unspecified

2015-11-12

Recent News Events

Date

Type

Title